Business

According to news reports, Pfizer has reversed its position on the closure of its R&D facility at Sandwich, UK, saving 350 jobs. The company's inhalation R&D group has operated out of Sandwich and had been in limbo after the company announced in February that it would be closing the site. Annette Doherty, the new site director at Sandwich, commented: "Pfizer's … [Read more...] about Pfizer reportedly retaining R&D at Sandwich site

The “Deep Draw Container Forming Method” developed by Mystic Pharmaceuticals for packaging of intranasal drugs for use with its VersiDoser and VRx2 intranasal delivery systems has been awarded US Patent No. 7,963,089. Both delivery systems use the proprietary unit dose blister packaging. The VersiDoser uses liquid-filled blisters, while the VRx2 reconstitutes freeze … [Read more...] about Mystic Pharmaceuticals receives patent for intranasal drug packaging technology

After receiving written guidance from the FDA in late May, says Generex, it has revised its development program for its Oral-lyn buccal insulin spray. A reorganized medical/regulatory group within the company will focus its efforts on providing information requested by the agency regarding the product's "preclinical, clinical, toxicology, manufacturing, and regulatory … [Read more...] about Generex reboots buccal insulin spray development program

The UK site where Pfizer has performed inhalation R&D is now on the market as "Discovery Park." The company announced the closing of the site, which employed 2400 people, in February 2011. Although a representative said, "The name Discovery Park reflects our hope that the site will continue, in part at least, to be a centre for research and development," the sales … [Read more...] about Pfizer puts Sandwich site up for sale

According to Perrigo Company, which is partnered with Teva on a generic triamcinolone acetonide nasal spray, Teva has begun shipping the product. Perrigo developed the nasal spray, which is a generic equivalent of Sanofi's Nasacort AQ, and is manufacturing it. The US FDA approved the application for the product for the treatment of nasal symptoms resulting from … [Read more...] about Teva begins shipping generic version of Nasacort AQ

Dry powder inhalation drug developer Savara Pharmaceuticals has graduated from the Austin Techonology Incubator (ATI) Bioscience Incubator, according to ATI. Savara, which was founded in 2007, is preparing for Phase 1 trials of its lead candidate, an inhaled antibiotic. “A transition from the laboratory into the clinic represents a significant accomplishment and … [Read more...] about Savara graduates from technology incubator

GlaxoSmithKline plans to expand its manufacturing facility in Mississauga, Ontario, in part to enable production of Relenza zanamivir dry powder for inhalation. The expansion is expected to create 70 new jobs. GSK will contribute more than $30 million, with the province of Ontario kicking in $3.6 million. Paul Lucas, President and CEO of GlaxoSmithKline Inc. said, … [Read more...] about GSK expanding Canadian facility